[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-364583-105":59,"doc-detail-364583-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","multicancer-detection-mcd-testing-in-gastrointestinal-cancers-an-evolving-tool-for-early-diagnosis","Multicancer Detection (MCD) Testing in Gastrointestinal Cancers - An Evolving Tool for Early Diagnosis","","This review summarizes the benefits and limitations of multicancer detection (MCD) tests for diagnosing gastrointestinal malignancies. It highlights how traditional GI screening varies by cancer type and may require invasive methods with limited sensitivity, while MCD offers a non-invasive blood-based approach using biomarkers such as cell-free DNA and RNA plus machine learning. Evidence from PATHFINDER and THUNDER supports feasibility and accuracy, but challenges remain, including cost, regulatory status, false positives, and limited data on whether testing reduces cancer-specific mortality.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/multicancer-detection-mcd-testing-in-gastrointestinal-cancers-an-evolving-tool-for-early-diagnosis/364583/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/multicancer-detection-mcd-testing-in-gastrointestinal-cancers-an-evolving-tool-for-early-diagnosis/364583.png","ImageObject",300,407,{"name":92,"@type":93},"Asher","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem do multicancer detection (MCD) tests aim to address in gastrointestinal cancers?","Question",{"text":112,"@type":113},"MCD tests aim to improve early detection by offering a non-invasive approach when standard GI screening options are limited by sensitivity and cancer-type variability.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How do MCD tests detect gastrointestinal cancers?",{"text":117,"@type":113},"MCD tests analyze biomarkers such as cell-free DNA and RNA from a simple blood draw, using advanced laboratory methods and machine learning to identify cancer-associated signals across multiple organ sites.",{"name":119,"@type":110,"acceptedAnswer":120},"What are the main limitations or challenges of MCD testing?",{"text":121,"@type":113},"Key challenges include high costs, lack of FDA approval, risk of false positives, limited clinical utility data for reducing cancer-specific mortality, and potential overdiagnosis-related effects such as patient anxiety and financial burden.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},364583,1790472637,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},687197207639,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Multicancer Detection (MCD) Testing in Gastrointestinal Cancers: An Evolving Tool for Early Diagnosis  \nAditya K. Ghosh1 · Kyle R. Stephens2 · Prem A. Kandiah3 · Ryan T. Hurt1 · Elizabeth A. Gilman1  \nAccepted: 26 February 2025 / Published online: 6 March 2025 © The Author(s) 2025  \nAbstract  \nPurpose of Review The current review aims to summarize the benefits and limitations of the novel multicancer detection tests (MCD) for diagnosing gastrointestinal (GI) malignancies.  \nRecent Findings Traditional cancer screening methods can reduce deaths in malignancies involving the GI tract. For GI cancers, screening options vary by type and often involve invasive techniques with limited sensitivity. MCDs offer a promising, non-invasive (simple blood draw) alternative by analyzing biomarkers such as cell-free DNA and RNA using advanced techniques and machine learning to detect cancers across multiple organ sites. Large studies like the PATHFINDER trial and THUNDER study have demonstrated the feasibility and accuracy of MCD assays in identifying cancer signals, with high sensitivity and specificity in some GI organs that lack routine screening tests (e.g., liver, pancreas, and stomach) . Despite these advancements, MCD testing faces challenges, including high costs, lack of FDA approval, false positives, and limited data on clinical utility in reducing cancer-specific mortality. MCD should not be a substitute for age-appropriate cancer screenings but may complement existing methods, particularly for cancers with no current screening tools, such as cholangiocarcinoma and pancreatic cancer. Clinicians need to discuss the limitations of MCDs, including the potential for overdiagnosis, patient anxiety, and financial burden due to insurance coverage gaps.  \nSummary MCD is a promising, non-invasive test that can augment traditional cancer screening. As the role of MCD in cancer detection evolves, further research is essential to establish how it will be integrated into clinical practice, ensuring informed, shared decision-making with patients.  \nKeywords Multicancer detection (MCD) test · Cancer screening · Gastrointestinal cancer  \nIntroduction  \nCancer screening has proven to be safe and effective at reducing mortality in cancers with available screening techniques. However, approximately 70% of cancer-related deaths in the United States are attributed to cancers that lack recommended screening tests [1] . Current screening methods for gastrointestinal (GI) malignancies vary by  \n􀀍 Aditya K. Ghosh [ghosh.aditya@mayo.edu](ghosh.aditya@mayo.edu)  \n1 Division of General Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA  \n2 University of Louisville School of Medicine, Hiram C. Polk Jr., M.D., Department of Surgery, Louisville, KY, USA  \n3 Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA  \ncancer type [2] . The most recommended screening options for colorectal cancer include Cologuard (Exact Sciences, Madison, Wisconsin), a DNA-based stool test, and a colonoscopy. Other screening options include fecal occult blood testing (FOBT), fecal immunochemical testing (FIT), and sigmoidoscopy [3] . Colonoscopy is the gold standard for diagnosing and treating pre-cancerous lesions at the time of testing. Still, it is limited by the adequacy of the preparation and the patient’s willingness to undergo an invasive procedure.  \nIn other GI malignancies, screening is limited and often includes invasive procedures [4] . For hepatocellular carcinoma (HCC), the American Association for the Study of Liver Diseases (AASLD) recommends ultrasound (US) every six months, with or without alpha-fetoprotein (AFP) testing, for patients with cirrhosis or chronic hepatitis B [5] . However, the US’s sensitivity is variable, and ongoing research into alternative imaging modalities and biomarkers  \nto improve early detection is underway [5] . For patients ata genetically heightened risk, such as those with BRCA2 and Lynch","cbCaidQmV9iIdCFZ","https://ap.wps.com/l/cbCaidQmV9iIdCFZ","pdf",983965,"English","# Abstract\n## Purpose of Review\n## Recent Findings\n## Summary\n# Introduction\n## Screening gaps in gastrointestinal cancers\n# Multicancer Detection (MCD) Testing","[{\"question\":\"What problem do multicancer detection (MCD) tests aim to address in gastrointestinal cancers?\",\"answer\":\"MCD tests aim to improve early detection by offering a non-invasive approach when standard GI screening options are limited by sensitivity and cancer-type variability.\"},{\"question\":\"How do MCD tests detect gastrointestinal cancers?\",\"answer\":\"MCD tests analyze biomarkers such as cell-free DNA and RNA from a simple blood draw, using advanced laboratory methods and machine learning to identify cancer-associated signals across multiple organ sites.\"},{\"question\":\"What are the main limitations or challenges of MCD testing?\",\"answer\":\"Key challenges include high costs, lack of FDA approval, risk of false positives, limited clinical utility data for reducing cancer-specific mortality, and potential overdiagnosis-related effects such as patient anxiety and financial burden.\"}]","Multicancer Detection (MCD) Testing in Gastrointestinal Cancers - An Evolving Tool for Early Diagnosis | PDF",1790158384,23,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b4e6b8e9b2e2c44c79c7bb20e6f5b383.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/37add435eaa9c6d795edfacb1535e778.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5e8b30adaef7f9d4dbfd5ac58b5abc58.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/037c8ed6890ba1684306115cae795b35.webp",980,1301]